Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-03-18FDA Approved: CARBAMAZEPINE — Supplemental Application (Apotex Corp.)
The FDA approved Apotex Corp.'s supplemental application for carbamazepine, a generic anticonvulsant. This action updates the approval statu…
-
CLINICAL_TRIALS trial_result · 2014-03-17Clinical Trial Update: Controlled Randomized Vagus Nerve Stimulation (VNS) Therapy Versus Resection (CoRaVNStiR) [NA]
Clinical trial comparing vagus nerve stimulation therapy to surgical resection for epilepsy; current status is unknown.
-
FDA approval · 2014-03-11FDA Approved: TOPIRAMATE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved the original application for Topiramate from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2014-03-10FDA Approved: EPITOL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for EPITOL (carbamazepine) from Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2014-03-07FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application to add KEPPRA XR, an extended-release formulation of levetiracetam, to the UCB product line.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-02-27FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Dilantin (extended phenytoin sodium) submitted by Viatris Specialty LLC.
-
FDA approval · 2014-02-27FDA Approved: PHENYTOIN INFATABS — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for PHENYTOIN INFATABS (phenytoin) from Prasco Laboratories under ANDA 084427.
-
CLINICAL_TRIALS trial_result · 2014-02-27Clinical Trial Update: The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients [Phase 1]
Phase 1 study evaluating the effect of BIA 2-093 on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. The trial stat…
-
CLINICAL_TRIALS other · 2014-02-27Clinical Trial Update: HOPE-Epilepsy Trial [Phase 2, Phase 3]
A HOPE-Epilepsy clinical trial (Phase 2/Phase 3) is currently suspended.
-
FDA approval · 2014-02-19FDA Approved: CARBAMAZEPINE — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals Limited's supplemental application for carbamazepine, a generic anticonvulsant.
-
FDA approval · 2014-02-19FDA Approved: CARBAMAZEPINE — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved a supplemental application for carbamazepine from Torrent Pharmaceuticals Limited, indicating updated authorization for the…
-
FDA approval · 2014-02-19FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for divalproex sodium from Unichem Pharmaceuticals (USA), Inc., indicating an approved change or add…
-
FDA approval · 2014-02-14FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved Eisai Inc.'s supplemental application for FYCOMPA (perampanel).
-
CLINICAL_TRIALS trial_result · 2014-02-14Clinical Trial Update: Animal Assisted Therapy in a Pediatric Setting [Phase 1, Phase 2]
Clinical trial update indicates an animal-assisted therapy study in a pediatric setting completed Phase 1 and Phase 2 trials across several …
-
CLINICAL_TRIALS trial_result · 2014-02-12Clinical Trial Update: Mindfulness-based Psychotherapy for Drug-resistant Epilepsy [NA]
A completed clinical trial evaluating mindfulness-based psychotherapy for drug-resistant epilepsy.
-
CLINICAL_TRIALS trial_result · 2014-02-12Clinical Trial Update: Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT [NA]
This is a completed extension study of Project UPLIFT focused on preventing depressive symptoms in people with epilepsy.
-
FDA approval · 2014-02-11FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for divalproex sodium from Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2014-02-05FDA Approved: DIVALPROEX SODIUM — Supplemental Application (NorthStar Rx LLC)
The FDA approved a supplemental application for divalproex sodium submitted by NorthStar Rx LLC.
-
CLINICAL_TRIALS trial_result · 2014-01-31Clinical Trial Update: Efficacy of YKP3089 in Patients With Photosensitive Epilepsy [Phase 2]
This update reports the completion of a Phase 2 trial evaluating the efficacy of YKP3089 in patients with photosensitive epilepsy.
-
CLINICAL_TRIALS trial_result · 2014-01-29Clinical Trial Update: Evaluation of Individual Bioequivalence of Gabasandoz® Relative to Neurontin® in Healthy Volunteers [Phase 1]
Phase 1 bioequivalence study comparing Gabasandoz to Neurontin (gabapentin) in healthy volunteers has completed.
-
FDA approval · 2014-01-27FDA Approved: PHENYTOIN SODIUM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for PHENYTOIN SODIUM from Hikma Pharmaceuticals USA Inc., granting the requested changes under an ap…
-
CLINICAL_TRIALS research · 2014-01-27Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.
A completed clinical trial evaluating the safety and efficacy of zonisamide as monotherapy or adjunctive therapy in adults with partial, gen…
-
FDA approval · 2014-01-24FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN-125 (phenytoin) submitted by Viatris Specialty LLC.
-
FDA approval · 2014-01-18FDA Approved: PHENYTOIN SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Phenytoin Sodium from Sun Pharmaceutical Industries, updating its existing approval. The drug is…
-
FDA approval · 2014-01-16FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Zarontin (ethosuximide) submitted by Parke-Davis Div of Pfizer Inc, reflecting an approved m…